The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T
Abstract
PURPOSE OF REVIEW: The aim of this study was to provide clinically relevant findings from the DRCR.net Protocol T, a multicentre randomized clinical trial comparing intravitreous aflibercept, repackaged (compounded) bevacizumab and ranibizumab for vision-impairing centre-involved diabetic macular oedema (DME). RECENT FINDINGS: At 1 year, all three antivascular endothelial growth factor (anti-VEGF) drugs, on average, improved visual acuity. There was no difference among drugs in mean change in visual acuity from baseline among eyes with baseline Snellen equivalent visual acuity of 20/32 to 20/40, whereas aflibercept yielded superior vision outcomes among eyes with baseline visual acuity of 20/50 to 20/320. At 2 years, aflibercept remained superior, on average, to bevacizumab, but not ranibizumab, among eyes with baseline visual acuity of 20/50 to 20/320. Over 2 years, in post-hoc area-under-the-curve analysis, aflibercept vision outcomes were superior to bevacizumab or ranibizumab among these eyes. All three drugs had comparable ocular and systemic safety profiles. The substantial cost differential between aflibercept and bevacizumab raises challenges when safety and efficacy are at odds with cost-effectiveness results. SUMMARY: When initial visual acuity loss is mild, there are no apparent differences, on average, among aflibercept, bevacizumab and ranibizumab for treating DME. When visual acuity loss is moderate or worse, aflibercept is more likely to improve visual acuity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.047 · Cited by 562
Self-citationBressler, S. B., Glassman, A. R., Almukhtar, T., Bressler, N. M., Ferris, F. L., Googe, J. M., Gupta, S. K., Jampol, L. M., Melia, M., & Wells, J. A. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.12.025 · Cited by 139
Self-citation
Cited by
Racial disparities in the screening and treatment of diabetic retinopathy
Coney, J. M., & Scott, A. W. (2022) · Journal of the National Medical Association · doi:10.1016/j.jnma.2021.12.011 · Cited by 53
Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L. (2025) · Eye · doi:10.1038/s41433-024-03529-9 · Cited by 14
Metadata
- Authors
- Cai, S., & Bressler, N. M.
- Venue
- Current Opinion in Ophthalmology
- Published
- 2017-11
- Volume
- 28
- Issue
- 6
- Pages
- 636-643
- ISSN
- 1040-8738 (ISSN-L)
- OpenAlex
- W2750410498
- Cited by
- 181
- References
- 2
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. https://app.cochat.ai/papers/10.1097/icu.0000000000000424
- The paper
- Cai, S., & Bressler, N. M. (2017). Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Current Opinion in Ophthalmology. https://doi.org/10.1097/icu.0000000000000424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.